MX348776B - Produccion personalizada de productos biologicos y metodo para reprogramar celulas somaticas. - Google Patents

Produccion personalizada de productos biologicos y metodo para reprogramar celulas somaticas.

Info

Publication number
MX348776B
MX348776B MX2013007633A MX2013007633A MX348776B MX 348776 B MX348776 B MX 348776B MX 2013007633 A MX2013007633 A MX 2013007633A MX 2013007633 A MX2013007633 A MX 2013007633A MX 348776 B MX348776 B MX 348776B
Authority
MX
Mexico
Prior art keywords
treat
animal
nucleic acid
cells
somatic cells
Prior art date
Application number
MX2013007633A
Other languages
English (en)
Other versions
MX2013007633A (es
Inventor
Theresa D Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of MX2013007633A publication Critical patent/MX2013007633A/es
Publication of MX348776B publication Critical patent/MX348776B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un in vitro para producir un polipéptido o proteína biológica terapéutica recombinante aislada para tratar una enfermedad que comprende transfectar una célula madre pluripotente producida sintéticamente (spPSC) con un ácido nucleico que codifica para dicho polipéptido o proteína biológica terapéutica recombinante, en condiciones en las que el polipéptido o proteína es expresada por dicha spPSC, y el polipéptido o proteína después es aislado de la spPSC, y la spPSC se produce a partir de una célula de un animal.
MX2013007633A 2011-01-03 2012-01-03 Produccion personalizada de productos biologicos y metodo para reprogramar celulas somaticas. MX348776B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161429409P 2011-01-03 2011-01-03
US201161431376P 2011-01-10 2011-01-10
PCT/US2012/020084 WO2012094321A1 (en) 2011-01-03 2012-01-03 Personalized production of biologics and method for reprogramming somatic cells

Publications (2)

Publication Number Publication Date
MX2013007633A MX2013007633A (es) 2015-07-14
MX348776B true MX348776B (es) 2017-06-28

Family

ID=45563510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007633A MX348776B (es) 2011-01-03 2012-01-03 Produccion personalizada de productos biologicos y metodo para reprogramar celulas somaticas.

Country Status (14)

Country Link
US (2) US9512200B2 (es)
EP (1) EP2661491A1 (es)
JP (2) JP6223829B2 (es)
KR (2) KR20170120726A (es)
CN (2) CN108017692A (es)
AU (1) AU2012204501B2 (es)
BR (1) BR112013018744B1 (es)
IL (1) IL227299B (es)
MX (1) MX348776B (es)
MY (1) MY161859A (es)
RU (1) RU2595390C2 (es)
SG (1) SG191836A1 (es)
WO (1) WO2012094321A1 (es)
ZA (1) ZA201305849B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916339B1 (en) 2013-10-31 2014-12-23 Vivex Biomedical, Inc. Spinal cord tissue dehydrated and micronized
WO2016088243A1 (ja) * 2014-12-05 2016-06-09 株式会社ニコン 判定装置、観察システム、観察方法、そのプログラム、細胞の製造方法、および細胞
US9402869B1 (en) 2015-03-27 2016-08-02 Vivex Biomedical, Inc. Treated neural tissue composition
CN107949390A (zh) * 2015-05-01 2018-04-20 赛斯卡医疗有限公司 用于治疗的自体骨髓的肌内施用
US10668109B2 (en) * 2015-06-18 2020-06-02 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
WO2017205559A1 (en) * 2016-05-25 2017-11-30 The Johns Hopkins University Engineered anucleate cellular and extracellular vesicles as a novel biologics delivery platform
CN111742044B (zh) 2017-10-03 2025-02-14 Sdf生物制药公司 用遗传修饰的β细胞治疗糖尿病
CA3092961A1 (en) * 2018-03-09 2019-09-12 Avrobio, Inc. Compositions and methods for treating parkinson's disease
CN111269878B (zh) * 2020-01-19 2022-02-11 深圳市北科生物科技有限公司 一种人多能干细胞转化为扩展多能干细胞的专用培养基及其应用
CN112143697B (zh) * 2020-10-08 2021-08-06 宁波希诺赛生物科技有限公司 一种促进胚胎干细胞增殖和分化的方法
US20220154148A1 (en) * 2020-11-18 2022-05-19 Xingxin Wang Methods for engineering human pluripotent stem cells for diabetes therapy by co-transduction

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
WO1999049015A2 (en) 1998-03-23 1999-09-30 Zymogenetics, Inc. Cardiac-derived stem cells
AU752942B2 (en) 1998-04-13 2002-10-03 Massachusetts Institute Of Technology Comb copolymers for regulating cell-surface interactions
JP4817514B2 (ja) * 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
WO2003101202A1 (en) 2002-05-31 2003-12-11 Osiris Therapeutics, Inc. Intraperitoneal delivery of genetically engineered mesenchymal stem cells
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
FR2878860A1 (fr) * 2004-12-08 2006-06-09 Vivalis Sa Lignees de cellules souches humaines derivees de cellules es et utilisations pour la production de vaccins et de proteines recombinantes
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
WO2007081631A2 (en) * 2006-01-04 2007-07-19 Healtheuniverse, Inc. Method of producing insulin-secreting cells from adult stem cells via transfection
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
AU2008297024B2 (en) * 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
WO2009091543A1 (en) * 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
US20090241206A1 (en) 2008-03-04 2009-09-24 University Of Iowa Research Foundation Methods for cloning ferrets and transgenic ferret models for diseases
US20110274670A1 (en) * 2008-06-13 2011-11-10 Myeong Jin Nam Mesenchymal stem cells which express human hepatic growth factor,manufacturing method thereof, and use thereof as therapeutic agent for liver diseases
WO2010022194A2 (en) * 2008-08-20 2010-02-25 Virxsys Corporation Compositions and methods for generation of pluripotent stem cells
DK2389434T3 (en) * 2009-01-26 2015-09-28 Pasteuria Bioscience Inc Novel pasteuria strain
CA2756833C (en) 2009-04-09 2019-11-19 Sangamo Therapeutics, Inc. Targeted integration into stem cells
JP2010268789A (ja) * 2009-04-24 2010-12-02 Kumamoto Univ 細胞医薬の製造方法

Also Published As

Publication number Publication date
US20120171722A1 (en) 2012-07-05
CN103403152A (zh) 2013-11-20
JP2018007660A (ja) 2018-01-18
IL227299A0 (en) 2013-09-30
AU2012204501B2 (en) 2016-05-19
JP6373459B2 (ja) 2018-08-15
MY161859A (en) 2017-05-15
WO2012094321A4 (en) 2012-09-20
RU2013136357A (ru) 2015-02-10
JP2014501118A (ja) 2014-01-20
EP2661491A1 (en) 2013-11-13
KR20140037036A (ko) 2014-03-26
RU2595390C2 (ru) 2016-08-27
MX2013007633A (es) 2015-07-14
US10030230B2 (en) 2018-07-24
IL227299B (en) 2020-06-30
US9512200B2 (en) 2016-12-06
BR112013018744A2 (pt) 2016-09-20
NZ613888A (en) 2015-07-31
KR20170120726A (ko) 2017-10-31
CN108017692A (zh) 2018-05-11
WO2012094321A1 (en) 2012-07-12
AU2012204501A1 (en) 2013-08-22
JP6223829B2 (ja) 2017-11-01
SG191836A1 (en) 2013-08-30
BR112013018744B1 (pt) 2022-03-29
US20170081641A1 (en) 2017-03-23
ZA201305849B (en) 2014-10-29

Similar Documents

Publication Publication Date Title
MY161859A (en) Personalized production of biologics and method for reprogramming somatic cells
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
MX2021000211A (es) Metodos y productos para transfeccion de celulas.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2018008733A (es) Metodos para extender la capacidad replicativa de las celulas somaticas durante un proceso de cultivo ex vivo.
MX2015017110A (es) Integracion dirigida.
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
MX363017B (es) Métodos y productos para la expresión de proteínas en células.
MX2017010217A (es) Sistema, aparato y metodo para la produccion de celulas y/o productos de celulas.
MX2022003994A (es) Produccion de oligosacaridos de leche humana en huespedes microbianos con importacion/exportacion dise?ada.
SG10201809152QA (en) Recombinant host cell for expressing proteins of interest
GB2555728A (en) Cancer cell enrichment system
PH12015501837A1 (en) Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recominbinant proteins
MX2018006063A (es) Medios y metodos de fermentacion para producir polisacarido en cultivo celular bacteriano.
GB2540694A (en) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
PH12012501982A1 (en) Selective extraction of proteins from saltwater algae
WO2011097181A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
PH12022550437A1 (en) Strains and processes for single cell protein or biomass production
NZ700897A (en) Lowering saturated fatty acid content of plant seeds
WO2011163531A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases
MX2021003567A (es) Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia.
ZA201704903B (en) Modified dnase and uses thereof
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
MY182519A (en) Method for producing lipid using acyl-acp thioesterase
MX2022003016A (es) Metodo de produccion con iones de cobre controlados.

Legal Events

Date Code Title Description
FG Grant or registration